World News Insights
1-3 Minute Gist
Support LyrArc
Reader contributions keep LyrArc open for everyone
Search, personalize, or simply browse. Follow the world around you from gist and context to insights.
Who we are | Our Credo | Ways of using Lyrarc | FAQ | Send Feedback | First Letter From the Editor
Sign up. It's free and easy to use
Create an account
to personalize your feed of articles and topics.
Direct From the Editor / On Topics Vital to the Nation
06/23/2026
Browse Articles or use Lyrarc's US patented "Groups" and "Links" for new insights. A Lyrarc Group of Articles on a topic gives insights into particular angles shown in the Group Title. A Lyrarc Link shows more specific insights for 2 articles.
Xi Jinping Tariff Negotiating Strategy with US Articles
LyrArc brings in selected articles from many of the world's top publications.
Articles are selected by experts and you can see the gist of the important articles.
LyrArc Article Gist
Anglo American CEO Cutifani says, "we are looking at every dollar and pulling everything back." He announced job cuts of 53,000, 35% of its workforce over 3 years. There is a sharp pullback by mining companies as the demand from China slows rapidly.
Anglo American CEO Cutifani says, "we are looking at every dollar and pulling everything back." He announced job cuts of 53,000, 35% of its workforce over 3 years. There is a sharp pullback by mining companies as the demand from China slows rapidly.
LyrArc Article Gist
Lower demand for Tecfidera, Biogen's drug for multiple sclerosis led to a drop of 22% in the company's share price. Because of the lower demand the 2015 revenue growth for Biogen will be 6-8% instead of 14-16% predicted earlier for the Cambridge, Mass. company. The lower demand is because of a rare side effect, patients discontinuing treatment because it was not helping, and lower reimbursement price in Germany. Tecfidera sales were $2.9 billion in 2014. Another factor is the competition from Gilenya for MS by Novartis.
Lower demand for Tecfidera, Biogen's drug for multiple sclerosis led to a drop of 22% in the company's share price. Because of the lower demand the 2015 revenue growth for Biogen will be 6-8% instead of 14-16% predicted earlier for the Cambridge, Mass. company. The lower demand is because of a rare side effect, patients discontinuing treatment because it was not helping, and lower reimbursement price in Germany. Tecfidera sales were $2.9 billion in 2014. Another factor is the competition from Gilenya for MS by Novartis.
LyrArc Article Gist
Anglo American responds to declining commodity prices and the slowdown in China with deep cuts of 53,000 jobs from its 151,000 workforce. Some of the jobs will be layoffs and other job cuts will be through sale of mines. In Australia mining employment is down 13% in the 2d quarter of 2015 over prior year. Anglo American plans to sell over a quarter of assets in the downsizing. BHP has spun off over ten mines into a separate company called South32. American Pittsburgh based company Consol Energy says it will no longer provide guaranteed health insurance to retired workers. Anglo American is one of the hardest hit companies. It had losses of $3 billion for the first half of 2015, and needs $1.5 billion in cost cutting to become profitable again.
Anglo American responds to declining commodity prices and the slowdown in China with deep cuts of 53,000 jobs from its 151,000 workforce. Some of the jobs will be layoffs and other job cuts will be through sale of mines. In Australia mining employment is down 13% in the 2d quarter of 2015 over prior year. Anglo American plans to sell over a quarter of assets in the downsizing. BHP has spun off over ten mines into a separate company called South32. American Pittsburgh based company Consol Energy says it will no longer provide guaranteed health insurance to retired workers. Anglo American is one of the hardest hit companies. It had losses of $3 billion for the first half of 2015, and needs $1.5 billion in cost cutting to become profitable again.
LyrArc Article Gist
Treatment costs with Praluent for cholesterol control are extremely high at $14,600 a year.
Treatment costs with Praluent for cholesterol control are extremely high at $14,600 a year.
Support LyrArc
We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.
Support Lyrarc from as small as $1
Copyright © 2006 - 2026 Intelilinks LLC
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us